Senior Director, Biostatistics
Braveheart Bio · Remote · San Francisco, CA or Remote or Hybrid · Posted November 19, 2026 (today)
- Remote · San Francisco, CA or Remote or Hybrid
Job description
About us
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
About the role
The Senior Director, Biostatistics, is a hands-on program-level statistical leader for our lead cardiovascular program, reporting to the VP, Head of Biometrics. The Senior Director serves as the program statistical lead for BHB-1893, owning the statistical strategy, design, analysis, and interpretation of late-stage Phase 2 and Phase 3 studies while doing much of the statistical work directly. The Senior Director manages CRO and vendor biostatistics and statistical programming work, collaborates closely with external partners, represents biostatistics on program teams and in health authority interactions, and drives the statistical components of regulatory filings. The ideal candidate brings deep late-stage and regulatory expertise, sound scientific judgment, and a strong preference for hands-on work in a lean, fast-moving biotech environment. This role is a key partner to Clinical Development, Clinical Operations, Data Management, Regulatory, Safety, Medical Affairs, and Clinical Pharmacology, and contributes to building the processes and standards of a growing late-stage organization.
Responsibilities
Serve as program statistical lead for BHB-1893, setting and executing the statistical strategy for Phase 2 and Phase 3 development across oHCM and nHCM, in alignment with the VP, Head of Biometrics
Provide statistical leadership on study design, including endpoint selection, sample size and power, randomization, estimands (ICH E9(R1)), multiplicity control, and adaptive or innovative designs where appropriate
Personally author statistical sections of protocols, statistical analysis plans (SAPs), DMC charters, randomization specifications, and TFL shells
Manage CRO and external biostatistics and statistical programming vendors day to day, including vendor selection, scopes of work, budgets, change orders, timelines, and quality of deliverables; hold vendors accountable and escalate issues as needed
Collaborate with external partners, including co-development or licensing partners, academic collaborators, steering committees, independent DMC statisticians, and key opinion leaders, to align on statistical strategy, analyses, and data sharing
Serve as statistical lead in interactions with FDA, EMA, and other health authorities, including End-of-Phase 2, Type B/C, and Scientific Advice meetings, and responses to agency questions
Lead statistical contributions to regulatory submissions (NDA/MAA), including integrated summaries of safety and efficacy (ISS/ISE), clinical study reports, and Module 2 summaries
Partner with Data Management and Statistical Programming on interim analyses, DMC data cuts, unblinding procedures and firewalls, database locks, and delivery of CDISC-compliant (SDTM/ADaM) datasets
Interpret and communicate study results to executive leadership, the Board, investigators, and external partners; support topline readouts, publications, and scientific presentations
Collaborate with Clinical Pharmacology and Translational Science on exposure–response, PK/PD, biomarker, and model-informed drug development analyses
Support medical affairs, real-world evidence, and health economics analyses, including exploratory and post-hoc analyses
Perform hands-on simulations, sample size and power calculations, and probability-of-success analyses to support study design and program decisions
Contribute to biostatistics SOPs, work instructions, templates, and standards, ensuring inspection readiness and compliance with GCP, ICH E9, and regulatory requirements
Perform independent statistical analyses and quality review of CRO outputs using SAS and/or R
Required experience & skills
MS or PhD in Biostatistics, Statistics, or a closely related quantitative field
At least 12 years of biostatistics experience with a PhD, or at least 15 years with an MS, within the biotechnology, pharmaceutical, or CRO industry
Direct experience as lead statistician on late-stage Phase 2 and Phase 3 programs, including dose-ranging and pivotal trials, from design through database lock, analysis, and reporting
Hands-on regulatory filing experience is required, having led or served as a senior statistician on at least one NDA, BLA, or MAA submission, including ISS/ISE, CDISC submission datasets, and responses to health authority questions
Deep expertise in clinical trial design, estimands, multiplicity, missing data methods, interim analyses, and group sequential and adaptive designs
Proven experience managing CROs and statistical vendors, with a track record of driving accountability, quality, and on-time delivery
Experience collaborating effectively with external partners, such as co-development or licensing partners, academic groups, and independent DMCs
Strong hands-on statistical skills, with the ability to independently perform analyses, simulations, and review of programming outputs; people management experience is not required
Working knowledge of SAS and/or R, CDISC standards (SDTM, ADaM), GCP, ICH E9/E9(R1), and relevant FDA and EMA guidance
Ability to communicate complex statistical concepts clearly to non-statisticians, including executives, the Board, investigators, and regulators
Demonstrated ability to work cross-functionally in a lean, fast-paced development environment
Strong written and verbal communication skills with a collaborative, team-oriented approach
Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity
Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude
Preferred experience & skills
Experience in cardiovascular clinical development, ideally including HCM or heart failure, and familiarity with endpoints such as peak VO2, KCCQ, NYHA class, and echocardiographic measures (e.g., LVOT gradient)
Experience supporting multiple regulatory filings and taking a product through approval and launch
Prior experience as program statistical lead in a small or mid-sized biotech transitioning into late-stage development
Experience preparing for or presenting at FDA Advisory Committee meetings
Experience with independent DMC/DSMB interactions and statistical reporting
Base Salary Range: $280,000 - $320,000
This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E ‑ Verify program to confirm employment authorization for all new hires.
To learn more about E-Verify please review this poster .
Posting 4512662009 on greenhouse. Source: the employer’s listing. Valid through January 3, 2027 unless closed earlier.